摘要
目的 观察替格瑞洛在急性ST段抬高型心肌梗死急诊经皮冠脉介入治疗（PCI）患者中的应用,分析其临床疗效.方法 行急诊冠脉介入治疗的急性心肌梗死62例患者,分为氯吡格雷组和替格瑞洛组,对比两组基线资料、PCI后即刻冠脉造影评价根据心肌梗死溶栓（TIMI）血流分级,30 d心血管不良事件和出血情况.结果 氯吡格雷组和替格瑞洛组年龄、性别及高血压病史率差异无统计学意义（P＞0.05）.替格瑞洛组术后即可恢复TIMI 3级血流率显著高于氯吡格雷组（96.7％ vs 87.5％,P＜0.05）,30 d再发心绞痛率低于氯吡格雷组（3.3％ vs 12.5％,P＜0.05）;两组患者30 d内全因死亡率差异无统计学意义（P＞0.05）,但轻微出血发生率替格瑞洛组高于氯吡格雷组（13.3％ vs3.1％,P＜0.05）.结论 替格瑞洛可以显著改善急性心肌梗死患者的临床症状和预后,但在国人中有增加出血风险的趋势.
Objectives To investigate clinic outcome of ticagrelor in treatment of patients with acute ST-segment elevation my ocardial infarction receiving primary percutaneous coronary intervention.Methods Sixty-two consecutive patients with ST segment elevation myocardial infarction （STEMI） receiving primary percutaneous coronary intervention （PCI） were included in this study.The clinic characteristics,thrombolysis in myocardial infarction （TIMI） refuse after PCI,clinical outcomes after 30 d of patients were compared between patients who were treated with ticagrelor （group A 30 cases） and clopidogrel （group B 32 cases）.Results There was no difference in the age,proportion of women,hypertension,and diabetics （P 〉 0.05）.TIMI 3 refuse after PCI were significantly higher in group A than group B （96.7% vs 87.5%,P 〈 0.05）.The 30 d re-angina pectoris was lower in group A than group B （3.3% vs 12.5%,P 〈0.05）.However,tiny bleeding of group A was higher than group B （13.3% vs 3.1%,P 〈0.05）.Conclusions Ticagrelortreatment can improve the prognosis of STEMI receiving primary PCI,but increase the risk of bleeding.
出处
《中国医师杂志》
CAS
2014年第9期1213-1215,共3页
Journal of Chinese Physician
基金
成都军区昆明总医院院管基金（2009Y019A）
成都军区学科带头人后备人才基金
关键词
血小板聚集抑制剂/治疗应用
心肌梗死/治疗
急性病
血管成形术
经腔
经皮冠状动脉
急诊处理
治疗结果
Platelet aggregation inhibitors/therapeutic use
Myocardial infarction/therapy
Acute disease
Angioplasty,transluminal,percutaneous coronary
Emergency treatment
Treatment outcome
